0HMP Stock Overview
A clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Bellerophon Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.035 |
| 52 Week High | US$0.17 |
| 52 Week Low | US$0.032 |
| Beta | 0.70 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | -99.14% |
| 5 Year Change | n/a |
| Change since IPO | -99.90% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0HMP | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | 4.7% | 1.4% |
| 1Y | n/a | -16.4% | 8.1% |
Return vs Industry: Insufficient data to determine how 0HMP performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how 0HMP performed against the UK Market.
Price Volatility
| 0HMP volatility | |
|---|---|
| 0HMP Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 7.0% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 9.5% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0HMP has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 0HMP's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 18 | Craig Jalbert | bellerophon.com |
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse, which is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness.
Bellerophon Therapeutics, Inc. Fundamentals Summary
| 0HMP fundamental statistics | |
|---|---|
| Market cap | US$440.38k |
| Earnings (TTM) | -US$9.25m |
| Revenue (TTM) | US$5.64m |
0.1x
P/S Ratio0.0x
P/E RatioIs 0HMP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0HMP income statement (TTM) | |
|---|---|
| Revenue | US$5.64m |
| Cost of Revenue | US$0 |
| Gross Profit | US$5.64m |
| Other Expenses | US$14.89m |
| Earnings | -US$9.25m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.76 |
| Gross Margin | 100.00% |
| Net Profit Margin | -164.06% |
| Debt/Equity Ratio | 0% |
How did 0HMP perform over the long term?
See historical performance and comparison